Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

A growing body of research has examined the IRA’s implications for pharmaceutical innovation. Much of this literature has focused on the potential impact on the number of new drug launches, 5, 6 but ...

Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more ...

Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...

The U.S. Food and Drug Administration (FDA) is moving to speed drug development and review by launching real-time clinical ...

WASHINGTON — Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a dual hub centered in the United States and China, according to ...

Barbara Slusher explains the hit-to-lead optimization process, high-throughput screening, and the role of AI and organoids in ...

By Sahil Pandey and Puyaan Singh April 14 (Reuters) - Amazon's cloud unit on Tuesday launched Amazon Bio Discovery, an ...

In this Q&A, Jenna DiRito, PhD, COO and co-founder of Revalia Bio, discusses how earlier, human-relevant data is reshaping go ...

Researchers at Kent have established a computational protocol that could accelerate the development of more effective ...

VANCOUVER, BC / ACCESS Newswire / April 23, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on ...

Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating ...